Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRD-Guided Post-Transplant Elranatamab Maintenance in Multiple Myeloma
NCT06483100Phase 2Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Dec 2024
- Primary completion
- Jun 2032
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of elranatamab in multiple myeloma (MM), sponsored by Washington University School of Medicine. Started Dec 2024; status: recruiting.
02
Drugs
elranatamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06483100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06483100.